In this article, we will discuss: 12 Best Genomics Stocks to Invest In.

Companies that study DNA to improve people’s lives are known as genomics stocks. These businesses often fit into one of three groups: genetic editing, genetic testing and diagnosis, or genetic sequencing and analysis.

Bloomberg reported on October 31, 2025, that the U.S. Food and Drug Administration announced a new regulatory route to expedite approvals for tailored gene-editing therapies. Vinay Prasad, the FDA’s director of gene therapies, stated that the agency is now allowing combination clinical trials involving individuals with associated genetic conditions, a departure from the previously required separate research for each disease.

According to Prasad, this approach takes advantage of CRISPR technology advancements and enables regulators to act more rapidly and readily, especially for extremely rare disorders that affect small patient populations. He stated that the policy aims to promote development and investment in areas that were previously thought to be commercially unsustainable.

Recently, in a report published in the American Journal of Human Genetics, researchers from the Children’s Hospital of Philadelphia and the University of Pennsylvania detailed how the FDA has permitted platform studies in which only the guide RNA is edited for certain mutations. As per the researchers, the approach might lower development costs and increase access to disorders, including phenylketonuria and urea cycle conditions.

With that said, here are the 12 Best Genomics Stocks to Invest In.

Our Methodology

We sifted through the online rankings to form an initial list of the 20 Best Genomics Stocks to Invest In. From the resultant dataset, we chose the 12 Best Genomics Stocks with the highest number of hedge fund holders for each stock using Insider Monkey’s database of hedge funds as of Q3 2025. We also considered analysts’ upside potential of over 15%, as of December 24. Finally, we ranked these stocks in ascending order based on hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

12. Personalis, Inc. (NASDAQ:PSNL)

Number of Hedge Fund Holders:  7   

Analysts’ Upside Potential as of December 24: 26.15%

Personalis, Inc. (NASDAQ:PSNL) is among the Best Genomics Stocks.

The Fly reported on December 2, 2025, that Morgan Stanley analyst Kallum Titchmarsh took over coverage of Personalis, Inc. (NASDAQ:PSNL) with an Equal Weight rating and a price objective of $11, up from $9. The firm identified several upcoming catalysts within its coverage universe starting in 2026 and outlined growing bright spots across life science instruments and diagnostics end markets. Morgan Stanley claimed that a valuation surge in the second half of the year left industry multiples at fair levels despite favorable sector dynamics, prompting the bank to start coverage with an In-Line industry stance.

In addition, Personalis, Inc. (NASDAQ:PSNL) lowered its full-year 2025 sales forecast from $70 million to $80 million to a range of $68 million to $73 million. The projected income from pharmaceutical testing, services, and other clients has been reduced from $52 million to $58 million to $50 million to $54 million.

In contrast to previous projections of $15 million to $16 million, revenue from population sequencing and enterprise clients was raised to $16.5 million to $17 million. Clinical test reimbursed revenue has dropped from $3 million to $6 million to $1.5 million to $2 million. Gross margin estimate of 22% to 24%, net loss of about $85 million, and cash consumption of about $75 million were all reiterated by the business.

Personalis, Inc. (NASDAQ:PSNL) offers genomic sequencing and analytics technologies to help develop tailored cancer vaccines and other next-generation cancer immunotherapies.

11. Absci Corporation (NASDAQ:ABSI)

Number of Hedge Fund Holders: 18 

Analysts’ Upside Potential as of December 24: 131.61%

Absci Corporation (NASDAQ:ABSI) is among the Best Genomics Stocks.

Absci Corporation (NASDAQ:ABSI) announced on December 4, 2025, that the first healthy volunteers had been dosed in the Phase 1/2a HEADLINE clinical trial investigating ABS-201, an experimental anti-prolactin receptor antibody built on its generative AI system. The Phase 1/2a trial is intended to evaluate effectiveness, pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability. The trial’s interim results are anticipated in the latter part of 2026. As per the company, ABS-201, which addresses indications in women’s health and dermatology, is a progression of its strategy to take internally produced assets into clinical development. According to founder and CEO Sean McClain, the achievement underlines the use of the AI-driven platform for clinical development and improves the delivery of unique assets.

Following an investor event centered on ABS-201 and its androgenetic alopecia program, the Fly reported on December 17, 2025, that H.C. Wainwright increased its price objective on Absci Corporation (NASDAQ:ABSI) to $8 from $7 and retained a Buy rating. The firm included ABS-201 in its financial model and noted how it might raise the percentage of hair follicles in the growth phase as opposed to the resting period, which is when hair loss takes place. The analyst stated that the strength of the preclinical evidence given throughout the event lends credibility to the ABS-201 program.

Absci Corporation (NASDAQ:ABSI) is an artificial intelligence-powered synthetic biology firm that is unlocking proteins’ potential as the next generation of drugs.

10. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Holders: 18  

Analysts’ Upside Potential as of December 24: 31.87%

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is among the Best Genomics Stocks.

On December 15, TheFly published that Luke Sergott, a Barclays analyst, lifted the price objective for Pacific Biosciences of California, Inc. (NASDAQ:PACB) from $1.50 to $2 and maintained an Equal Weight rating for the shares. As part of its 2026 forecast, the company modified price objectives and ratings in the life sciences and diagnostics tools area. The analyst informs investors in a research note that the final estimate cuts, improving end markets, and the fact that tools are the most undervalued space in healthcare offer a very favorable backdrop for the tools group to beat the market in 2026.

Separately, last quarter’s revenue came in slightly less than the company’s projections, at $38.4 million, mainly due to fewer than expected Vega sales in Europe and lower than anticipated revenue on ASPs.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) anticipates an improvement in the fourth quarter with sequential revenue growth of about 10%. The company noted that revenue growth will be driven by higher Revio placements and the sustained strength in consumables observed throughout the year. It reduced sales projections for the entire year 2025 to a range of $155 million to $160 million.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) creates innovative DNA sequencing technology to aid researchers in better understanding complex genomes.

9. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 19 

Analysts’ Upside Potential as of December 24:  81.92%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the Best Genomics Stocks.

Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on December 19, 2025, according to a report published in TheFly.

On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price objective of $11 instead of $10. According to the firm, REC-4881 proved solid and long-lasting effectiveness in treating familial adenomatous polyposis.

The analyst informs investors in a research note that REC-4881’s addressable market is now larger than anticipated, providing explosive potential. JPMorgan has a 60% chance of success and peak revenues of more than $1 billion. Furthermore, per JPMorgan, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s CDK7 inhibitor REC-617 has proven early anti-tumor effectiveness in platinum-resistant ovarian cancer.

The company has reiterated its 2025 forecast with an expense base of less than $450 million, which does not include any inflows from partnerships. The overall forecast for 2026 has been maintained at less than $390 million. It is also anticipated that the cash position will sustain operations until the end of 2027 without the need for further funding.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology business.

8. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 21  

Analysts’ Upside Potential as of December 24: 20.98%

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Best Genomics Stocks.

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74. The firm stated that the modification came after revisions to its business model following the third-quarter report.

Besides that, it was reported on December 22, 2025, that CRISPR Therapeutics AG (NASDAQ:CRSP) offered clinical updates on zugocaptagene geleucel. It is also known as zugo-cel (previously CTX112), an experimental allogeneic CAR T treatment that targets CD19 for hematologic malignancies and autoimmune diseases. A Phase 1 basket trial for autoimmune rheumatologic disorders is now evaluating Zugo-cel. Four patients treated with a 100 million cell dose and monitored for at least 28 days exhibited cell expansion similar to that observed at the same dose in B-cell lymphoma trials as of the December 17, 2025, data cut-off. B-cell depletion was seen to occur quickly and persistently in one to two days. On Day 28, all patients had considerable clinical improvement. A patient with systemic lupus erythematosus who was unresponsive to nine previous treatments continued to experience drug-free DORIS clinical remission through the sixth month of treatment.

As of November 20, 2025, ten patients with refractory or relapsed large B-cell lymphoma were receiving treatment at the recommended Phase 2 dose of 600 million cells for hematologic malignancies. There were reports of a 90% overall response rate and a 70% full response rate. After 12 months of follow-up, 67% of patients were in full response.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing firm that focuses on the development of CRISPR/Cas9-based therapies.

7. Twist Bioscience Corporation (NASDAQ:TWST)

Number of Hedge Fund Holders: 24  

Analysts’ Upside Potential as of December 24: 46.15%

Twist Bioscience Corporation (NASDAQ:TWST) is among the Best Genomics Stocks.

TheFly reported on December 15, 2025, that Barclays kept its Overweight rating and boosted its price objective for Twist Bioscience Corporation (NASDAQ:TWST) from $37 to $39. The move was included in the company’s more comprehensive 2026 outlook report for the life sciences and diagnostics instruments industry. According to Barclays, end markets are rebounding, the last round of estimate cutbacks has mostly passed, and the healthcare industry’s most under-owned sector is still tools. Based on the company’s research note given to investors, all of these factors provide a favorable setting for the tools group to exceed expectations in 2026.

Furthermore, Twist Bioscience Corporation (NASDAQ:TWST) released fiscal 2026 guidance. The business anticipates total revenue to be between $425 million and $435 million, which implies an increase of between 13% and 15.5% year over year. Revenue for the DNA Synthesis and Protein Solutions Group is anticipated to reach $194 million to $199 million, representing a 15% to 18% rise over fiscal 2025. It is projected that the NGS Applications Group will make between $231 million and $236 million, showing a rise of 11% to 13.5%. The fiscal year 2026 gross margin is expected to go above 52%. Apart from that, the firm announced its goal to end fiscal 2026 with adjusted EBITDA breakeven in the fourth quarter.

Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology business that has created a disruptive DNA synthesis platform to industrialize biological engineering.

6. Veracyte, Inc. (NASDAQ:VCYT)

Number of Hedge Fund Holders: 25 

Analysts’ Upside Potential as of December 24: 16.75%

Veracyte, Inc. (NASDAQ:VCYT) is among the Best Genomics Stocks.

The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40. According to the firm, the Life Science Tools and Diagnostics end markets are showing rising bright spots, and various catalysts will be present across its coverage by 2026. Nonetheless, multiples are now at fair levels due to an industry valuation surge in the second part of the year. As a result, Morgan Stanley started the group with an In-Line industry perspective and designated Danaher as its Top Pick.

Veracyte, Inc. (NASDAQ:VCYT) also boosted guidance for the entire year 2025. The total sales forecast went from $496 million to $504 million to $506 million to $510 million. Meanwhile, testing revenue projections increased from $477 million to $483 million to $484 million to $487 million. The guidance for adjusted EBITDA margin has been elevated from 23.5% to over 25%. Testing sales growth was previously predicted to be between 14% and 15%, but it is now anticipated to be 16%. The company anticipates that without certain extra expenditures, the adjusted EBITDA margin will be roughly 25% in the fourth quarter and in subsequent years.

Veracyte, Inc. (NASDAQ:VCYT) is a company that does genomic diagnostics.

5. Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 27   

Analysts’ Upside Potential as of December 24: 61.84%

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the Best Genomics Stocks.

TheFly reported on December 2, 2025, that Beam Therapeutics Inc. (NASDAQ:BEAM) has released revised safety and effectiveness information from its BEACON Phase 1/2 clinical trial evaluating ristoglogene autogetemcel (previously BEAM-101). It is an investigational genetically engineered ex vivo base editing cell therapy for sickle cell disease patients suffering from severe vaso-occlusive crises. The information was shown during the 67th Annual Meeting and Exposition of the American Society of Hematology in Orlando.

A total of 31 adults and adolescents were treated with risto-cel and were included in the updated results. The company reported a decline of hemoglobin S to less than 40%, a remission of anemia that lasted up to 20 months, and a mean fetal hemoglobin induction of more than 60%. A median of one cell collection cycle was needed for each patient. After treatment, rapid neutrophil and platelet engraftment were seen. According to the firm, busulfan conditioning, autologous hematopoietic stem cell transplantation, and preexisting sickle cell disease did not affect the safety profile.

Separately, Beam Therapeutics Inc. (NASDAQ:BEAM) was covered by Evercore ISI on November 24, 2025, with a $35 price target and an Outperform rating. BEAM-302 was mentioned by the analyst as a possible treatment for alpha-1 antitrypsin insufficiency. Levels of adjusted alpha-1 antitrypsin production were seen in early data. The analyst noted that new data anticipated in the first quarter of 2026 will be critical.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology firm focused on developing a new class of precision genetic therapies based on its own base editing technique to give patients with severe illnesses permanent solutions.

4. Prime Medicine, Inc. (NASDAQ:PRME)

Number of Hedge Fund Holders: 30  

Analysts’ Upside Potential as of December 24: 63.78%

Prime Medicine, Inc. (NASDAQ:PRME) is among the Best Genomics Stocks.

Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has published Phase 1/2 clinical results for PM359, its experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition. Prime Editing for p47-phox Chronic Granulomatous Disease is a publication that presents preliminary data from two individuals treated in a Phase 1/2 trial intended to assess safety, biological function, and initial effectiveness in both adult and pediatric participants. Prior CGD-defining problems were seen in both patients. Each had fast neutrophil engraftment, with 69% and 83% dihydrorhodamine-positive neutrophils by Day 30. Following infusion, neither patient experienced any new CGD-related problems or serious concurrent illnesses. The observed toxicities were compatible with busulfan-based conditioning, and no clinically relevant adverse events linked to PM359 were documented.

As reported by TheFly, LifeSci Capital started covering Prime Medicine, Inc. (NASDAQ:PRME) on December 23, 2025, with an Outperform rating and a $6 price target. LifeSci Capital noted that the business is creating one-and-done gene editing treatments for conditions like cystic fibrosis, Wilson’s disease, and alpha-1 antitrypsin deficiency that have an extensive unmet demand. The firm stated it is optimistic about the potential in Wilson’s disease and alpha-1 antitrypsin deficiency.

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology business focused on providing genetic medicines to treat diseases through the use of gene editing technology, known as Prime Editing.

3. Tempus AI, Inc. (NASDAQ:TEM)

Number of Hedge Fund Holders: 32  

Analysts’ Upside Potential as of December 24: 38.49%

Tempus AI, Inc. (NASDAQ:TEM) is among the Best Genomics Stocks.

TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95. The shares were still rated as a buy by analyst Kyle Mikson. As noted by Canaccord, the sector momentum that started in the latter half of 2025 can continue into 2026, based on a preview of its coverage of life science instruments and diagnostics.

BofA also reduced its price estimate for Tempus AI, Inc. (NASDAQ:TEM), from $90 to $80 on December 15, 2025. Analyst Michael Ryskin reaffirmed a neutral recommendation on the stock. According to the BofA, the change was a component of a more comprehensive upgrade to price objectives for all of the life sciences and diagnostic tool companies that fall under its umbrella. As per the firm, headwinds should lessen, and markets should return to normal in 2026.

BofA further stated that it anticipates a rebound in biopharma spending to provide the biggest boost for the industry. The firm stated that it supports businesses that have more involvement in research and development.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology business. It provides molecular genotyping, polymerase chain reaction profiling, next-generation sequencing diagnostics, and other anatomic and molecular pathology tests to medical professionals, pharmaceutical firms, biotechnology businesses, researchers, and other third parties.

2. GeneDx Holdings Corp. (NASDAQ:WGS)

Number of Hedge Fund Holders: 34 

Analysts’ Upside Potential as of December 24: 20.43%                            

GeneDx Holdings Corp. (NASDAQ:WGS) is among the Best Genomics Stocks.

TheFly reported that on December 22, 2025, GeneDx Holdings Corp. (NASDAQ:WGS) lifted its price objective at Canaccord from $160 to $170. Canaccord continued to rate the shares as a Buy. The firm stated that the industry’s momentum, which started in the second half of 2025, can continue into 2026 and gave a preview of its coverage of life science instruments and diagnostics. Canaccord noted that it had the strongest conviction in the company’s risk-reward profile and potential for share price growth among the businesses it covered.

Separately, on December 15, 2025, Wells Fargo boosted its target price for GeneDx Holdings Corp. (NASDAQ:WGS) from $140 to $155. The stock was rated Equal Weight by Wells Fargo. According to the firm, there is potential for improvement due to less ambiguity surrounding U.S. policy on pharmaceuticals and already solid forward growth projections. Wells Fargo stated that under these conditions, it supports the structure for tool firms.

In the most recent quarter, President and CEO of the business, Stueland, noted the company’s plan to push forward high-profitable growth by announcing an increase in the 2025 revenue projection to between $425 million and $428 million.

GeneDx Holdings Corp. (NASDAQ:WGS) provides health insights to guide treatment, promote drug discovery, and aid in diagnosis. The business is in a unique position to make precision medicine the norm by accelerating the application of genomic and extensive clinical data.

1. Wave Life Sciences Ltd. (NASDAQ:WVE)

Number of Hedge Fund Holders: 38 

Analysts’ Upside Potential as of December 24: 83.64%

Wave Life Sciences Ltd. (NASDAQ:WVE) is among the Best Genomics Stocks.

TheFly reports that on December 19, 2025, H.C. Wainwright upgraded Wave Life Sciences Ltd. (NASDAQ:WVE)’s price target from $22 to $30. Analyst Andrew Fein upheld the Buy rating. H.C. Wainwright cited 9.4% visceral fat loss and 3.2% lean mass gain with no gastrointestinal problems to support WVE-007 as a possible body recomposition agent, using key opinion leader validation and dose-response modeling. According to the firm, higher doses may expedite fat loss, and a clean safety profile supports a distinct commercial label.

Visible Alpha reported on the same day that Wave Life Sciences Ltd. (NASDAQ:WVE) shares soared by 147% on December 8 following the company’s presentation of preliminary clinical data for WVE-007, an RNA-based obesity therapy. Three months after a single dose, early data from a small research study revealed sustained fat reduction, including drops in visceral and total fat.

Visible Alpha consensus forecasts that risk-adjusted revenue for WVE-007 is expected to increase from $26 million to approximately $68 million in 2030 and from $1 billion to $2.1 billion by 2040. It is anticipated that by 2040, the drug candidate will account for 15% of the company’s revenue, climbing to 47%. The company’s total revenue is projected to reach  $459 million in 2030 and $4.5 billion by 2040.

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology firm dedicated to achieving the vast promise of RNA therapies, commonly known as oligonucleotides, which target RNA to transform human health.

While we acknowledge the potential of WVE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WVE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. 12 Best Genomics Stocks to Invest In is originally published on Insider Monkey. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.